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Abstract
BACKGROUND: The platinum-iodohistamine complex with in
vitro cytostatic activity toward colon and mammary cancer cells
has been synthesised recently in our laboratory. The pharma-
cokinetics of radioactive complex analogues, labelled with
I-131 and I-125, has been examined in murine model of sponta-
neous mammary adenocarcinoma. The present work is devot-
ed to the examination of the potential use of liposomes as
a carrier system for the radioactive platinum-[*I]iodohistamine
complex in vivo.
MATERIAL AND METHODS: Encapsulations of the Pt-
[125I]iodohistamine were studied using a different molar ratio of
the complex and liposomes with positive surface charge, as
well as various incubation procedures. Biodistribution of the
initial and the liposomal form of the complex were studied in
C3H tumour-bearing mice with spontaneously developed and
transplantable (16C) mammary adenocarcinoma.
RESULTS: Comparative biodistribution studies in C3H/16C mice
and in mice with spontaneously developed mammary tumour
have shown that in the former model pharmacokinetics of the
Pt-[125I]iodohistamine complex is more predictable and more
similar to that observed for cisplatin. Therefore, the transplant-
able tumour model is more advantageous for the complex and
its liposomal form evaluation.
In C3H/16C mice, significant differences in the biodistribution
between the radioactive platinum complex and its liposomal
form were observed. The concentration of the activity in blood
after 2 h p.i.v. was two times lower for the encapsulated com-
plex, and the uptake of the radioactivity by liver, spleen, and
lungs was twice as high as that obtained for the free
Pt-[125I]iodohistamine preparation. The radioactivity in tumour
was almost constant for liposomal platinum complex (ca. 2%
ID/g), although it was two times lower compared to the initial
platinum complex.
CONCLUSIONS: The results of the present study indicate that
platinum-[*I]iodohistamine can be efficiently incorporated into
cationic liposomes (c. 40%). However, the uptake of the encap-
sulated complex by the liver and spleen macrophages demands
further modification of the lipid membrane.
Key words: platinum-[125I]iodohistamine complex, cationic
liposomes, spontaneous mammary adenocarcinoma in C3H
mice, tumour-bearing C3H/16C mice
Introduction
It has been demonstrated both in the laboratory and in clinical
trials that a concomitant combination of irradiation and chemo-
therapeutic agents enhance the efficacy of the tumour cells killing
[1–5]. Cisplatin, as well as other platinum-based anticancer drugs,
is an excellent radiosensitiser, therefore in combination with ex-
ternal irradiation or with low-dose continuous internal radiothera-
py it produces significant supra-additive treatment effects toward
several tumour cells. Recently, we have synthesised the new
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platinum-[*I]iodohistamine complexes (Fig. 1) containing platinum
(II) core and the radiotherapeutic isotope — the moieties of a plau-
sible synergistic anti-cancer potency [6]. The “cold” complex dem-
onstrated the cytostatic activity in vitro toward mammary and co-
lon cancer cells [7]. The radioactive analogue of platinum-iodohis-
tamine complex, i.e., labelled with iodine-131 (b-emitter) or iodine-
125 (prolific emitter of Auger electrons), should produce a locally
effective therapeutic dose in tumour cells or masses in vivo. This
may be achieved by radiosensitisation of the cells, or by inhibition
of the intracellular repair mechanism. The obtained data of the
previous investigation have shown promising features of the newly
developed platinum-[*I]iodohistamine complexes, and suggest their
potential application for the therapy of solid tumours [7].
However, a rational approach to the development of cyto-
statics involves the use of carrier functions that cause specific ac-
cumulation of the respective compounds in the target organs or in
the target cells. Liposomes, artificial lipid-based vesicles, have been
widely studied as drug delivery systems due to their relative safety,
their structural versatility concerning size, composition and bilayer
fluidity, and their ability to incorporate almost any molecule regard-
less of its structure [8–11]. Therefore, the liposomes of sterically
stabilised membrane (stealth-liposomes) have been already utilised
for several anticancer drugs targeting, for instance doxorubicyn
(Caelyx or Doxil) or daunorubicyn (Daunoxone), etc. There have
also been attempts to apply liposomes for cisplatin encapsulation,
and some of the results are promising [10, 12, 13].
Considering a weak solubility of platinum(II)-[*I]iodohistamine
in aqueous media, as well as a high in vivo accumulation of the
complex in liver and gastrointestinal tract (GIT) [7], the use of lipo-
somes for the complex delivery seems promising. This paper de-
scribes the preliminary radiochemical and biological studies on
PtCl2-[
125I]iodohistamine complex encapsulated within “normal”
cationic liposomes. In addition, the presented results provide data
for consideration of the choice between the two animal models of
mammary adenocarcinoma for the drug evaluation in vivo.
Material and methods
The platinum(II)Cl2-[
125I]iodohistamine complex was synthe-
sised according to the developed procedure [6], by heating the
solution of platinum(II) tetrachloride ion with the mixture of radio-
iodinated histamine (i.e. 125I-histamine) and the carrier-added
iodohistamine. The stock solutions of the platinum-iodohistamine
complexes were prepared in dimethylformamide (DMF). The esti-
mated specific activities of the Pt(II)-[125I]iodohistamine prepara-
tions used for biodistribution studies were in the range of 0.8 to
5 MBq/mmol of Pt. For in vivo studies, the injections of platinum
[125I]iodohistamine complex were prepared in 0.9% saline con-
taining 25% of DMF.
Liposomes with a cationic charge of the surface were formed in
the presence of stearylamine (18 mmol), phosphatidylcholine
(63 mmol), and cholesterol (9 mmol) (Sigma kit L4395). Hydration of
the lipid mixtures was done in saline at 65oC followed by downsiz-
ing the lipid suspensions by filtration through 0.2 mm polycarbon-
ate membrane, and finally by sonication using ultrasonic bath. With
this procedure, typically, small unilamellar vesicles with diameters
in the range of 50–100 nm are formed [9, Avantilipids: Technical
Information]. Encapsulation of the Pt-[125I]iodohistamine was stud-
ied using a different molar ratio of the complex and lipid, as well as
various incubation procedures. The yield of the complex entrap-
ment into liposomes was monitored by TLC, radioelectrophoresis
and RP HPLC. The liposomal platinum complexes were isolated by
gel filtration using a glass column (15/1 cm) filled with Sephadex
G-25F, and/or by solid phase extraction using SPE C18 cartridges
and gradient of EtOH concentration in saline.
The comparative biodistribution studies of the preparations of
the platinum complex, i.e. free Pt-[125I]iodohistamine and the com-
plexes encapsulated within liposomes, were done in two models
of mammary adenocarcinoma in C3H mice. The experiments were
performed using female C3H/W mice with developed spontane-
ous mammary adenocarcinoma (purchased from the Department
of Genetics and Laboratory Animal Breeding Cancer Centre and
Institute of Oncology, Warsaw, Poland), and using tumour-bear-
ing C3H mice about 20 days after subcutaneous injection of the
stabilised 16C cells of mammary adenocarcinoma (Institute of Im-
munology and Experimental Therapy of Wrocław). Mice with tu-
mour diameter of c. 0.8–1 cm were used.
The platinum-[125I]ihistamine complex under study and its li-
posomal forms were administered intraperitoneally in a volume of
0.1 ml and dose of about 0.5 MBq per one animal. At selected
time, 2 and 24 hrs after dosing, the animals were anaesthetised
and killed, and then the organs were taken out to determine the
distribution of radioactivity. The radioactivity of blood pool, urine,
and samples of weighted tissues and carcass were measured
using a gamma counter supplied with an adapter for whole body
measurement. The results were calculated as a percentage of the
injected dose in organs (%ID) or a percentage of dose in gram of
tissue (%ID/g). An unpaired Student t-test (at 95% confidence in-
terval) was applied for data evaluation. The animal experiments
were approved by The 4th Local Animal Ethics Committee in War-
saw (authorisation number ZT/27/2002), and were carried out in
accordance with the principles of good laboratory practice.
Results and discussion
Encapsulation of PtCl2-[*I]iodhistamine
The yields of the complex entrapment into liposomes var-
ied in the function of applied method as follows: Method 1
— freeze-drying liposomes, rehydration with saline in the pres-
ence of the complex dissolved in 20% DMSO — yield c. 80%;
Figure 1. The structure of Pt(II)Cl2-[*I]iodohistamine(N3,N
a) complex.
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Method 2 — incubation of the solutions of liposomes and the complex
(in 20% DMF) at 65oC with vortexing and sonication — yield 15 to
30%; Method 3 — freeze-drying liposomes with the complex following
by rehydration with 10-percentaged DMF in saline — yield c. 40%.
The highest yield of the platinum-[125I]iodohistamine encapsu-
lation (c. 80%) was achieved using Method 1, i.e. after mixing the
complex solution in DMSO with the freeze-dried liposomes in the
molar ratio of the lipid to Pt 1.5:1, following rehydration with saline
and incubation for 1 hr at 65°C with shaking and occasional soni-
cation. However, further studies have shown that DMSO signifi-
cantly affected the structure of the complex. Therefore, Method 3,
which produced a satisfactory yield of the complex entrapment into
liposomes (c. 40%; Fig. 2), has been used for the liposomal forms
of the radioactive platinum-[125I]iodohistamine complex preparation.
Choice of the tumour model
Biodistribution study of the native radioactive platinum-
-[125I]iodohistamine complex on the two models of mammary
adenocarcinoma revealed about four times higher accumulation
of the complex in tumour than in normal muscular tissue (Fig. 3A, B).
Anyhow, a significant difference of the complex pharmacokinet-
ics has been observed for the two tumour models used. A high
radioactivity retention in blood (over 14% ID/ml after 2 h p.i.) has
been observed in mice bearing spontaneous mammary carcino-
ma, and that implied also a high radioactivity concentration in tu-
mour and other tissues. However, decrease of radioactivity in tu-
mour was observed after 24 h p.i. (3.75% ID/g after 2 h and 2.30%
ID/g after 24 h p.i.). In contrast, a significantly lower blood con-
centration of the complex was observed 2 h p.i. in the trans-
plantable tumour model (C3H/16C), although retention of the com-
plex in the tumour increased with the time after administration (from
1.63% ID/g to 3.53% ID/g after 2 h and 24 h p.i., respectively, Fig. 3B).
The comparative biodistribution studies have shown that the
pharmacokinetics of the complex in C3H/16C mice is more pre-
dictable and more similar to that observed for cisplatin [14, 15].
Thus, it can be assumed that retention of the complex undergoes
the same mechanisms that are strictly connected with a higher
metabolism and/or angiogenesis of the tumour masses. Other
studies revealed also the fundamental differences between trans-
plantable and spontaneously arising tumours in mice [16, 17],
and these facts support our assumption. Therefore, it seems that
the model with transplanted stabilised 16C cells of mammary ad-
enocarcinoma is more convenient for drug evaluation than the
murine model with spontaneously developed tumour. Consider-
ing accumulation of the complex in 16C tumour, which suggests
penetration of the complex into the tumour cells, we have chosen
this model for further evaluation of the complex encapsulated within
liposome.
In vivo evaluation of the Pt(II)-[125I]iodohistamine
liposomal form
In vivo study of the complex and its liposomal forms in C3H/
/16C tumour-bearing mice has shown differences in biodistribu-
tion between the two complex forms mainly after 24 h p.i. (Fig. 3B,
Fig. 4). The encapsulated complex revealed a high and almost
constant concentration in liver and spleen, and a significant clear-
ance from GIT, whereas the retention of the free complex in these
organs showed the opposite tendency. The liposomal platinum
complex was also more rapidly cleared from the blood, and its
almost two times higher excretion with urine was also noted.
Some advantages of platinum-[*I]iodohistamine encapsulation in
cationic liposomes could be observed in vivo (e.g. lower concen-
tration in GIT), however, in general it has not produced significant-
ly better pharmacokinetics compared to that of the free complex.
The radioactive concentration of the liposome-encapsulated com-
plex in tumour was constant (c. 2% ID/g) at the studied time points
(Fig. 4), whereas for the “free” complex an increment of concen-
tration was observed after 24 h p.i. to the level twice higher than
those for the liposomal form.
Conclusions
The present study indicates that Pt(II)Cl2-[
*I]iodohistamine
complex can be efficiently incorporated into cationic liposomes.
These types of liposomes have previously demonstrated efficacy
in animal models of human diseases, and are currently being eval-
Figure 2. The exemplary RP HPLC radio-chromatograms: (upper) solu-
tion of Pt(II)-[125I]iodohistamine complex, (lower) reaction mixture of Pt(II)
-[125I]iodohistamine encapsulation within cationic liposomes (Method 3).
(Luna C18 150/4.6 mm Phenomenex; mobile phase: 0.05 M NaClO4/80%
AcN/5% DMF; oven temp. 40oC; isocratic, flow rate 0.5 ml/min; radiometric
detection on-line).
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uated in human clinical studies [8, 11, 18]. It has been shown that
cationic liposomes can mediate efficient delivery of DNA and DNA/
/protein complex to mammalian cells in vitro and in vivo. Finally,
human tumour cells selected for cisplatin resistance or isolated
from patients who have failed cisplatin therapy are highly trans-
fectable with cationic liposomes [11]. However, the observed up-
take of the encapsulated complex by the liver and spleen mac-
rophages, as well as its low concentration in the tumour tissue
observed in our study, demands further modification of the lipid
membrane. We also tested neutral in charge, large multilamellar
liposomes (9.3 mmol phosphatidylcholine and distearoyl, 6.9 mmol
cholesterol; pre-liposome formulation Sigma L3406) as in vivo
carriers of the complex, although without any success. Taking into
account a variety of the existing protocols for coating liposomes
surface, which extend liposome blood circulation times and de-
crease uptake of encapsulated complex by the liver and spleen
macrophages, future optimisation of the specific system for tar-
Figure 4. Accumulation of Pt(II)Cl2-[
125I]iodohistamine complex encapsu-
lated within cationic liposomes in the selected tissues of C3H/16C
tumour-bearing mice (mean and 1SD of the % ID/g, n = 5).
geting of the platinum-radiopharmaceutical should be perhaps
possible. We hope it may also increase the concentration of the
radioactive platinum-[*I]iodohistamine complex in tumour cells sig-
nificantly, but confirmation of these expectations demands further
studies.
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